Kosuke Higashida
Yokohama City University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kosuke Higashida.
Metabolism-clinical and Experimental | 2000
Koji Kobayashi; Shin Amemiya; Kosuke Higashida; Toshihide Ishihara; Emi Sawanobori; Kisho Kobayashi; Mie Mochizuki; Nobuyuki Kikuchi; Kunpie Tokuyama; Shinpei Nakazawa
We attempted to identify the pathogenic factors involved in the progression to type 2 diabetes in obese Japanese adolescents. Subjects included 18 nondiabetic obese adolescents, 12 obese adolescents with type 2 diabetes on diet therapy, 10 obese adolescents with type 2 diabetes manifesting ketosis at onset or with a history of treatment with hypoglycemic agents, and 26 non-obese adolescent control subjects. The first-phase insulin response (FPIR), glucose disappearance constant (Kg), glucose effectiveness (Sg), and insulin sensitivity (S(I)) were obtained using an insulin-modified frequently sampled intravenous glucose tolerance test (FSIGT) and a minimal model analysis. The disposition index (DI, by FPIR x S(I)) was determined to assess any endogenous insulin effect. The results showed that Kg was decreased significantly (P = .0006) with the progression to severe diabetes in the obese groups. Although S(I) and Sg did not differ significantly among the 3 obese groups, both parameters were significantly lower in each obese group versus the non-obese controls. As a result of the significant decrease in FPIR (P < .0001), the DI decreased (P = .0006) with the progression to severe diabetes in the obese groups. In conclusion, an early manifestation of type 2 diabetes with occasional ketosis at onset may result from beta-cell dysfunction to glucose stimulation. This finding is demonstrated by the relatively low FPIR to decreased S(I) in obese Japanese adolescents, as well as the low Sg as a synergic role in glucose intolerance. The present findings from a Japanese population for pathogenic factors aside from obesity may help us to gain a better understanding of the progression to adolescent, early-onset, obese type 2 diabetes and its severity.
Hormone Research in Paediatrics | 1999
Kisho Kobayashi; Shin Amemiya; Mie Mochizuki; Koji Kobayashi; Kyoko Matsushita; Emi Sawanobori; Toshihide Ishihara; Kosuke Higashida; Yoshie Shimura; Kiyohiko Kato; Shinpei Nakazawa
We attempted to clarify the association between angiotensin-converting enzyme (ACE) gene polymorphism and the other predictive factors for macroangiopathy in children and adolescents with uncomplicated insulin-dependent diabetes mellitus (IDDM). Sixty-three patients were divided into 3 groups according to the ACE genotypes. The lipid profiles were evaluated according to ACE genotypes. The level of lipoprotein(a) (Lp(a)) in the II genotype was significantly lower than that in groups with the D allele. Lp(a) significantly correlated with apo B/apo A-I (p < 0.001, r = 0.63) and atherogenic index (AI = (total cholesterol – high-density lipoprotein cholesterol)/high-density lipoprotein cholesterol; p = 0.004, r = 0.36). We suggest that the D allele may affect the level of Lp(a) and the other lipid profiles in IDDM.
Nephron extra | 2011
Hiroaki Kanai; Emi Sawanobori; Anna Kobayashi; Kyoko Matsushita; Kanji Sugita; Kosuke Higashida
Background: There is no clear consensus as to which patients with Henoch-Schönlein purpura nephritis (HSPN) at risk of a poor outcome should be treated and what therapeutic regimen should be used. Methods: Nine children with heavy proteinuric HSPN received prompt initiation of methylprednisolone pulse therapy (MPT) combined with tonsillectomy in a prospective study. Results: At presentation, the mean values for the patients’ urine protein excretion (early-morning urinary protein/creatinine ratio), serum IgA, activity index (AI), and chronicity index (CI) were 5.0 ± 5.6 g/g Cr, 135.6 ± 56.5 mg/dl, 4.0 ± 0.7, and 1.7 ± 1.3, respectively. At the second biopsy, conducted approximately 24 months after initiation of therapy, the patients’ serum albumin had significantly increased (4.4 ± 0.2, p < 0.01), and the serum IgA and AI had significantly decreased (88.1 ± 30.8 mg/dl, p < 0.05; 2.0 ± 1.2, p < 0.01, respectively), whereas the CI remained unchanged. Proteinuria disappeared within 24 months in all but 1 patient, and hematuria disappeared within 38 months in all patients. No patient showed renal impairment or experienced a recurrence and/or exacerbation of HSP/HSPN. Conclusions: Early treatment with MPT combined with tonsillectomy is effective in ameliorating the histopathological progression and improving the clinical course of children with heavy proteinuric HSPN.
Clinical Nephrology | 2014
Hiroaki Kanai; Emi Sawanobori; Keiichi Koizumi; Ryuji Ohashi; Kosuke Higashida
Post-streptococcal glomerulonephritis (PSGN) generally has a good renal prognosis, and immunosuppressive therapies are not needed. However, a few patients present with severe acute kidney injury and extensive crescent formations. The etiology of such patients is not well known, and involvement of anti-neutrophil cytoplasmic antibodies is rarely reported. A 9-year-old girl with rapidly progressive nephritic syndrome was diagnosed with PSGN. A biopsy showed diffuse crescentic glomerulonephritis with immunoglobulin G and C3 deposits; moreover, humps were observed on electron microscopy. After she was administered methylprednisolone pulse therapy and intravenous cyclophosphamide, followed by prednisolone and azathioprine therapy, her urinary abnormalities improved and renal function normalized. However, the myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) titers gradually increased. We speculated that PSGN may be augmented by increased MPO-ANCA levels. Therefore, the patient is currently being treated with losartan, enalapril, azathioprine, and prednisolone. Although the MPO-ANCA titer remains high, urinary findings show mild proteinuria and her renal function has been norma for 18 months since onset. A progressive clinical course and severe histological findings may indicate the involvement of ANCA in deterioration of condition in patients with PSGN. Furthermore, in such cases immunosuppressive therapies should be considered even in pediatric PSGN.
Pediatrics International | 2018
Hiroaki Kanai; Emi Sawanobori; Anna Kobayashi; Miwa Goto; Kosuke Higashida; Kanji Sugita
The aim of this study was to assess the diagnostic value of urinary fibrin/fibrinogen degradation products (uFDP) measured using an anti‐fibrinogen antibody in patients with orthostatic proteinuria (OP), and their use in differentiating between OP and glomerulonephritis (GN).
Endocrine Journal | 1999
Kisho Kobayashi; Shin Amemiya; Koji Kobayashi; Emi Sawanobori; Mie Mochizuki; Toshihide Ishihara; Kosuke Higashida; Masaichi Miura; Shinpei Nakazawa
Endocrine Journal | 2000
Kisho Kobayashi; Koji Kobayashi; Mie Mochizuki; Kyoko Matsushita; Emi Sawanobori; Toshihide Ishihara; Kosuke Higashida; Shin Amemiya
Endocrine Journal | 1998
Shin Amemiya; Kisho Kobayashi; Koji Kobayashi; Mie Mochizuki; Emi Sawanobori; Toshihide Ishihara; Kosuke Higashida; Kenji Ohyama; Shinpei Nakazawa
Pediatric Infectious Disease Journal | 1997
Kosuke Higashida; Kisho Kobayashi; Kanji Sugita; Naoko Karakida; Yoshiko Nakagomi; Emi Sawanobori; Yoshimi Sata; Masao Aihara; Shin Amemiya; Shinpei Nakazawa
Clinical Pediatric Endocrinology | 1994
Shin Amemiya; Emi Sano; Kosuke Higashida; Toshihide Ishihara; Kouji Kobayashi; Kishou Kobayashi; Kenji Ohyama; Shinpei Nakazawa; Kiyohiko Kato; Fumihiko Kurimoto